Mallinckrodt Names Leslie Donato to Board of Directors
Mallinckrodt (NYSE:MNK) has appointed Leslie Donato to its Board of Directors, completing its nine-member board following the recent merger with Endo, Inc. As former Executive Vice President and Chief Strategy Officer of Cencora, Donato brings over 30 years of healthcare industry experience and a track record of executing successful M&A strategies, having deployed over $10 billion in capital at Cencora and contributing to a 130% market cap increase over five years.
The appointment follows Mallinckrodt's August 1, 2025 merger with Endo, creating a global therapeutics leader. The board now comprises four members from each legacy company, with Donato jointly selected as the ninth member. Her extensive experience includes leadership roles at Bayer Healthcare Pharmaceuticals and McKinsey & Company.
Mallinckrodt (NYSE:MNK) ha nominato Leslie Donato nel suo Consiglio di Amministrazione, completando così il consiglio composto da nove membri dopo la recente fusione con Endo, Inc. In qualità di ex Vicepresidente Esecutivo e Chief Strategy Officer di Cencora, Donato porta con sé oltre 30 anni di esperienza nel settore sanitario e un solido record nell'attuazione di strategie di M&A di successo, avendo gestito oltre 10 miliardi di dollari di capitale in Cencora e contribuendo a un aumento del 130% della capitalizzazione di mercato in cinque anni.
La nomina segue la fusione avvenuta il 1° agosto 2025 tra Mallinckrodt e Endo, che ha dato vita a un leader globale nel settore terapeutico. Il consiglio ora è composto da quattro membri di ciascuna delle due aziende originarie, con Donato scelta congiuntamente come nono membro. La sua vasta esperienza include ruoli di leadership presso Bayer Healthcare Pharmaceuticals e McKinsey & Company.
Mallinckrodt (NYSE:MNK) ha designado a Leslie Donato para su Junta Directiva, completando así su consejo de nueve miembros tras la reciente fusión con Endo, Inc. Como ex Vicepresidenta Ejecutiva y Directora de Estrategia de Cencora, Donato aporta más de 30 años de experiencia en la industria sanitaria y un historial de ejecución exitosa de estrategias de fusiones y adquisiciones, habiendo gestionado más de 10 mil millones de dólares en capital en Cencora y contribuyendo a un aumento del 130% en la capitalización bursátil en cinco años.
El nombramiento sigue a la fusión del 1 de agosto de 2025 entre Mallinckrodt y Endo, que creó un líder global en terapéuticos. La junta ahora está compuesta por cuatro miembros de cada empresa original, con Donato seleccionada conjuntamente como el noveno miembro. Su amplia experiencia incluye cargos de liderazgo en Bayer Healthcare Pharmaceuticals y McKinsey & Company.
Mallinckrodt (NYSE:MNK)는 최근 Endo, Inc.와의 합병을 마무리하며 9인 이사회 구성을 완료하기 위해 Leslie Donato를 이사회에 임명했습니다. 전 Cencora의 부사장 겸 최고전략책임자인 Donato는 30년 이상의 의료 산업 경험과 성공적인 인수합병 전략 실행 실적을 보유하고 있으며, Cencora에서 100억 달러 이상의 자본을 운용하고 5년간 시가총액을 130% 증가시키는 데 기여했습니다.
이번 임명은 2025년 8월 1일 Mallinckrodt와 Endo의 합병에 따른 것으로, 글로벌 치료제 선도 기업이 탄생했습니다. 이사회는 각 회사 출신 4명씩 총 8명과 Donato가 공동으로 선출된 9번째 멤버로 구성되어 있습니다. 그녀는 Bayer Healthcare Pharmaceuticals와 McKinsey & Company에서 리더십 역할을 수행한 풍부한 경험을 갖추고 있습니다.
Mallinckrodt (NYSE:MNK) a nommé Leslie Donato à son conseil d'administration, complétant ainsi son conseil de neuf membres suite à la récente fusion avec Endo, Inc. Ancienne vice-présidente exécutive et directrice de la stratégie chez Cencora, Donato apporte plus de 30 ans d'expérience dans l'industrie de la santé et un solide parcours dans la mise en œuvre de stratégies de fusions-acquisitions réussies, ayant déployé plus de 10 milliards de dollars de capital chez Cencora et contribué à une augmentation de 130 % de la capitalisation boursière en cinq ans.
Cette nomination fait suite à la fusion du 1er août 2025 entre Mallinckrodt et Endo, créant un leader mondial des thérapeutiques. Le conseil comprend désormais quatre membres de chaque entreprise d'origine, Donato ayant été choisie conjointement comme neuvième membre. Son expérience étendue inclut des postes de direction chez Bayer Healthcare Pharmaceuticals et McKinsey & Company.
Mallinckrodt (NYSE:MNK) hat Leslie Donato in seinen Vorstand berufen und damit den neunköpfigen Vorstand nach der jüngsten Fusion mit Endo, Inc. vervollständigt. Als ehemalige Executive Vice President und Chief Strategy Officer von Cencora bringt Donato über 30 Jahre Erfahrung in der Gesundheitsbranche mit und verfügt über eine nachweisliche Erfolgsbilanz bei der Umsetzung erfolgreicher M&A-Strategien, wobei sie bei Cencora über 10 Milliarden US-Dollar Kapital eingesetzt und zu einer 130%igen Steigerung der Marktkapitalisierung in fünf Jahren beigetragen hat.
Die Ernennung erfolgt nach der Fusion von Mallinckrodt mit Endo am 1. August 2025, die einen globalen Therapeutik-Führer geschaffen hat. Der Vorstand besteht nun aus jeweils vier Mitgliedern der beiden Vorgängerunternehmen, wobei Donato gemeinsam als neuntes Mitglied ausgewählt wurde. Ihre umfangreiche Erfahrung umfasst Führungspositionen bei Bayer Healthcare Pharmaceuticals und McKinsey & Company.
- Strategic appointment brings extensive healthcare industry expertise with over 30 years of experience
- Completion of board structure following major Endo merger positions company for integrated governance
- New director's track record includes executing $10B+ in M&A deals and achieving 130% market cap growth at Cencora
- None.
Appointment of Former Cencora Executive Completes Nine-Member Board
An accomplished healthcare industry executive with broad expertise across strategy, corporate development, marketing, commercialization, and product development, Ms. Donato most recently served as Executive Vice President and Chief Strategy Officer of Cencora, Inc., a leading global pharmaceutical solutions organization. While at Cencora, she executed an ambitious M&A and growth strategy, committing over
Her appointment follows Mallinckrodt's announcement on August 1, 2025, that it had completed its merger with Endo, Inc., to create a global, scaled, diversified therapeutics leader. The company's board now consists of four members from each of the legacy companies, and Ms. Donato, who was jointly selected by her fellow board members.
"We are delighted to welcome Leslie to Mallinckrodt's Board of Directors," said Board Chair Paul Efron. "Her wealth of experience in the healthcare industry will inform the board's strategic discussions and provide valuable insight for setting the direction of the company. We look forward to the contribution that we know Leslie will make to the board's decision-making at Mallinckrodt."
Ms. Donato's career in healthcare spans more than 30 years. Prior to Cencora, which she joined in 2019, Ms. Donato spent 10 years at Bayer Healthcare Pharmaceuticals, where she led a number of businesses before becoming the head of strategy. Prior to Bayer, Ms. Donato was a partner at McKinsey & Company, where she spent 14 years helping executives improve performance as the leader of the firm's Pharmaceutical & Medical Products Marketing & Sales Practice and a founding partner of its
"I am privileged to have the opportunity to help shape Mallinckrodt's new future," said Ms. Donato. "The teams from Mallinckrodt and Endo, who are now joined under one company, are poised for greater success, and I could not be more excited to join the board at a pivotal moment in the company's history."
Ms. Donato also serves on the board of Virtua Health System, a leading academic nonprofit healthcare system in southern
About Mallinckrodt
Mallinckrodt is a leading provider of life-enhancing therapeutics focused on addressing unmet patient needs and a world-class manufacturer of high-quality generics, sterile injectables, and active pharmaceutical ingredients.
Our company consists of multiple wholly owned subsidiaries that operate in two businesses. Our Brands business is focused on autoimmune and rare diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients. To learn more, visit www.MNK-Endo.com.
Contacts
Investors
Bryan Reasons
Executive Vice President and Chief Financial Officer
bryan.reasons@mnk.com
Media
Michael Freitag / Aura Reinhard / Catherine Simon
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
Mallinckrodt, the "M" brand mark, the Mallinckrodt Pharmaceuticals logo, Endo and the Endo logo are trademarks owned or licensed by a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2025.
View original content to download multimedia:https://www.prnewswire.com/news-releases/mallinckrodt-names-leslie-donato-to-board-of-directors-302519822.html
SOURCE Mallinckrodt plc
FAQ
Who is Leslie Donato and what is her role at Mallinckrodt (MNK)?
How many members are on Mallinckrodt's board after Leslie Donato's appointment?
What is Leslie Donato's professional background before joining Mallinckrodt's board?
When did Mallinckrodt complete its merger with Endo?
What were Leslie Donato's achievements at Cencora?
